Amazing investment opportunity
BRSF 0,75 0,00 0,00%

Brain Scientific is a top growth pick for
2021 and beyond

sing up for investor updates:

Stay updated on company news and announcements

Why Invest in Brain Scientific

Revolutionizing the EEG market, making neurological care affordable & accessible to all
Major disruptor with a cheaper, simpler & more practical alternative to conventional technology.
Owner of 2 patented, FDA approved products for wirelessly connected EEG test technologies.
Positioned for explosive growth due to a severe access shortages (70% of hospitals lock EEGs)
Developing long-term monitoring capabilities using the Nobel Prize graphene materials.
Massive market of over 100 million patients in the USA alone.
Closely aligned with telemedicine & Med-Tech sectors ( continuous Quarter over Quarter growth).
Highly experienced executive team In all relevant fields with proven track records.
Why Invest

Global Market Potential

Massive Patient Base

These patients include people of all ages: TBls and head traumas arriving in ICUs and EDs as well as suffers of epilepsy, Alzheimer’s, dementia, strokes, seizures, sleeping disorders, migraines, and encephalitis.

EEG tests are vastly undersupplied throughout the US, and globally it’s worse. This is due to a lack of readily available hardware, which is already operated on dated technology and equipment, The shortage is exacerbated by a lack of trained and qualified medical staff to administer and then interpret the results of the EEG tests.

5 million

ICU ond ED potients ore condldotes for EEGs eoch yeor, yet only-25% of these receive the test because departments do not hove the available technology or speciolists

5.8 million

Alzhelmers suffers In the USA – I person diognosed with it every 65 seconds in the us

1.6-3.8 million

Concussion occur each year ln the USA.

3.4 million

SI.lifers of epilepsy notionwide.

50-70 million

US odults hove o sleeping disorder

30 million

Migraine suffers in the USA.

1 person per min.

Is offected by encepholltis In the US.

16.2 million

Suffers of depression
– Most common In those oged 18-25

800,000 per year

In the USA someone hos o stroke every 40 seconds.

Sources: World Health Organization & Johns Hopkins

Brain Scientific is a great opportunity for seasoned
industry veterans as well as first time investors.


ICU and ER patients

Epilepsy and Alzheimer’s sufferers

Migraine, Sleep Disorder, Encephalitis, and Stroke, patients.

  • 1 in 6 Americans are currently affected by brain disease

  • A globally aging population is increasing the shortage of specialists to conduct and interprete EEGs.

  • Less than 1% of US hospitals are level 4 epilepsy center, with 24/7 EEG coverage

  • Only 30% of US hospitals have the equipment and on-hand professionals to perform an EEG

Sources: alz.org, cdc.gov, americanbrainfoundation.org

Market Growth

Huge Market Growth Potential

This is an early stage investment with huge growth potential because of its inclusion in multiple markets that are expec ted to expand rapidly over the next few years:
  • Medtech Market – Growing at a CAGR of 5% from $176.7 billion in 2020 to $262.4 billion in 2028
  • Telemedicine Market – Growing at a CAGR of 23.5% from $34.2 billion in 2018 to $185.6 billion in 2026
  • Brain Scientific’s advanced technology brings EEGs to millions of patients in widely underserved markets 
  • These revolutionary, cost effective, Medtech products will vastly widen the availability of EEGs and bring neurological care to the masses through teleneurology

Sources: www.grandviewresearch.com

The growth prospect of this opportunity is as certain as the fact that the world’s population is getting older, every single day.

COVID Aftermath

Sources: www.worldometers.info/coronavirus/worldwide-graphs/

In the aftermath of COVID-19 doctors the world over are finding that many of those who contracted coronavirus have acquired long-lasting neurological conditions.

There is no detailed knowledge of what these neurological conditions may be or may mean for the afflicted. EEGs are going to be instrumental in diagnosing and organizing treatment for those afflicted.

Brain Scientific’s revolutionary technological advancements in the world of EEGs are going to be key players in the rapid advancement of neurological discoveries and treatment insights in this area. This represents a huge opportunity for growth the company valuation.

Product Market Fit

In the US a rapidly aging population Is creating a shortage of neurologists, and 20 states have fewer than 10 neurologists per 10,000 patients. These areas are called ‘neurology deserts’. Worldwide, there are neurology deserts much larger than those in the US, which leaves a large percentage of world’s population untreated because their neurological afflictions go undiagnosed.

THIS MARKET IS RIPE FOR TECHNOLOGICAL INNOVATION, AND PUBLICLY TRADED COMPANIES, LIKE BRAIN SCIENTIFIC ARE LEADING THE CHARGE.
  • Brain Scientific’s goal is to eradicate these neurology deserts in the USA and make EEGs accessible to everyone
  • Making EEGs widely available using their proprietary technology Brain Scientific (BRSF) sees a significant Increase in its stock price in the future.

New Advanced Technology

Brain Scientific’s two patented and FDA approved products, NeuroCap™ and NeuroEEG™ have already disrupted the EEG mar1cet and thrust it into 21st century by, reducing size, and incorporating wireless bluetooth technology and secure cloud storage.

Over 80% reduction in setup time

(from 30 minutes to 5 minutes)

Can be fitted by anyone who received minimal training

Patented and FDA approved

Disposable, eliminating the chance of spreading infection

Small and completely portable

Doesn’t require acutely trained technicians or on-hand neurologists

(massive advantage over current systems)

Backwards with existing 3rd party systems

Brain Scientific has commenced development of its market disrupting proposed Brain E-Tattoo device for the brain diagnostics market, utilizing revolutionary, Nobel Prize winning material graphene, which is expected to feature minimally invasive, subcutaneous graphene electrode implants paired with a micro EEG. The proposed Brain E-Tattoo device is expected to allow for long-term monitoring capabilities and uninterrupted data collection from patients with neurological conditions such as epilepsy, Alzheimer’s disease, stroke, and other brain disorders.

Via a graphene based electrode system connected to a micro EEG that is clipped behind the ear, signals are collected by the sensors and wirelessly and securely stored in the cloud, where Al performs continuous analysis.

Both of these technologies are market disruptors. Integration with Al and machine learning will enable faster, more accurate diagnostics, improved predictability of events such as strokes and seizures before they actually happen, and enable a better standard of care.

Brain Scientific is a great opportunity for seasoned industry veterans as well as first time investors.


Excellent investment opportunity.

Play a part in developing predictive algorithms for epilepsy, Alzheimer’s, and Parkinson’s disease.

This investment is speculative, illiquid, and involves a high degree of risk, including the possible loss of your entire investment. For risks relating to this offering, see the Subscription Agreement for this offering.
New Investors, Group

Use it like a pro

We believe the future of EEG testing will be centered around the ability to gather more precise data through non-invasive measures of the brain via 3D temporary imprint or implanted graphene electrodes. By utilizing graphene, which has been called a “wonder material of the 21st century”, Brain Scientific believes the size of the electrodes can be thinner than a human hair and will allow brain activity monitoring with minimal distraction from everyday life.”

“Our current EEG device is about the size of a stamp. By shrinking the technology, the system allows for continuous measurement during a person’s normal activities, while providing a non-intrusive way to monitor various disorders,”

Boris Goldstain, Co-Founder & Executive Chairman

The Team

Baruch Goldstein

Co-Founder & Executive Chairman

Dr. Baruch Goldstein has over two decades of experience in neuro-net informatics, brain image recognition and processing, artificial intelligence and management of robotic systems. Goldstein’s growth-focused leadership style has helped him raise over $750 million in venture capital to develop innovative companies and startups in diverse industries.

  • Built a suite of first-to-market companies as a technology-oriented leader, including RYAH MedTech, Brain Scientific, GrapheneCA, E-Forex and Intelligent Video Systems Co-Founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics
  • Co-Founded BrainRX, a company specializing in pre-Alzheimer’s diagnostics

DR. Nickolay Kukekov

Ph.D. Director

Dr. Nickolay V. Kukekov is a founding partner at HRA Capital and a Senior Managing Director at Paulson Investment Company. He previously worked as a senior healthcare investment banker at a number of healthcare boutique firms that include Rodman & Renshaw, Paramount Capital, Summer Street Research Partners, Merriman Capital, etc.

Through his illustrious career, Kukekov has attained a Bachelor’s degree in Molecular, Cellular and Developmental Biology from the University of Colorado at Boulder and a Ph.D. in Neuroscience from Columbia University, College of Physicians and Surgeons in New York. Along the way, he has picked up several prestigious research scholarship awards and been featured in various peer-review publications.

Amy Griffith

Vice President of Strategy & Business Development

Amy Griffith is a seasoned professional and an innovative sales expert with years of experience in the medical and healthcare industries. She leads the development of strategic and tactical initiatives and new sales strategies for Brain Scientific. Previously, Griffith has held senior positions at technology companies and has worked with numerous start-ups on creating and implementing strategic sales programs. At Glaxosmithkline, she promoted a product portfolio to over 400 psychiatrists, neurologists, internists, OB/GYN, and family practice physicians.

Irina Nazarova

Marketing Director

Irina Nazarova is a media and marketing professional with an extensive journalism background, specializing in Content Strategy, Digital Marketing, and Public Relations.

She previously held a CEO role at 7+7 Media, Inc. In 2010-2016, she was a publisher of DOM-2 Magazine and Moscow: Instructions for Use Newspaper. Nazarova graduated from The New School (Media Management) and Moscow State University (Journalism).

In Summary

Brian Scientific (OTC:BRSF) is a top stock pick for 2021, expecting exceptional growth in the very near future. Two patented, FDA approved devices are going to lead the expansion of EEGs and the availability of neurological care through the new, high growth market of teleneurology. This is an opportunity not to be missed! Brain Scientific will soon be the lead player in the neurology tech space with tt1eir revolutionaty, 3rd party compatible equipment which will soon be present In every market in the USA.

“How many millionaires do you know who have become wealthy by investing in savings accounts? I rest my case.” — Robert G. Allen

New Investors, Group
Brain Scientific Main Focus

Latest Press Releases

Brain Scientific Main Focus is to modernize the brain diagnostic market by employing cutting edge technologies to bridge the widening gap in access to neurological care.
Brain Scientific Unveils New Initiative to Develop Brain E-Tattoo Device for the Brain Diagnostics Market

Brain Scientific Unveils New Initiative to Develop Brain E-Tattoo Device for the Brain Diagnostics Market

News

Powered by A.I., Brain E-Tattoo Technology is Expected to Provide Continuous Monitoring for Uninterrupted Data Collection in Patients with Epilepsy, Alzheimer’s, Stroke, and More.

Brain Scientific To Enter the U.S. Pediatric Market with NeuroCap™ for Children

Brain Scientific To Enter the U.S. Pediatric Market with NeuroCap™ for Children

News
The New Product Offering will Bring Advanced, Disposable EEG Technology to Pediatric Clinicians across the Country. The NeuroCap for children is designed to address the need for comfort, speed, and reliability within the pediatric population.
Brain Scientific, Creator of Next Gen Neurology Technologies, Announces Regulation A+ Offering

Brain Scientific, Creator of Next Gen Neurology Technologies, Announces Regulation A+ Offering

News

Widening Its Investor Network Will Allow Brain Scientific to Continue Its Work in Creating Advanced Technology Devices and Software for the Neurology Market.


Our main mission as an independent research group is to raise awareness of investment opportunities that can help us bring new solutions to the industry.

Marketplace

Contact Us

info@newinvestorsgroup.com
© New Investors Group. All rights reserved.

Forward-Looking Statement Disclaimer: This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,” “projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar words. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements: (i) the initiation, timing, progress and results of the Company’s research, manufacturing and other development efforts; (ii) the Company’s ability to advance its products to successfully complete development and commercialization; (iii) the manufacturing, development, commercialization, and market acceptance of the Company’s products; (iv) the lack of sufficient funding to finance the product development and business operations; (v) competitive companies and technologies within the Company’s industry and introduction of competing products; (vi) the Company’s ability to establish and maintain corporate collaborations; (vii) loss of key management personnel; (viii) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its products and its ability to operate its business without infringing the intellectual property rights of others; (ix) potential failure to comply with applicable health information privacy and security laws and other state and federal privacy and security laws; and (x) the difficulty of predicting actions of the USA FDA and its regulations. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement unless required by law. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is contained under the heading "Risk Factors" in Ehave, Inc.’s Registration Statement on Form F-1 filed with the Securities and Exchange Commission (SEC) on September 24, 2015, as amended, which is available on the SEC's website, http://www.sec.gov.

Safe Harbor: Statements in this presentation that are not descriptions of historical facts are forward-looking statements relating to future events, and as such all forward-looking statements are made pursuant to the Securities Litigation Reform Act of 1995. Statements may contain certain forward-looking statements pertaining to future anticipated or projected plans, performance, and developments, as well as other statements relating to future operations and results. Any statements in this presentation that are not statements of historical fact may be considered to be forward-looking statements. Words such as “may,” “will,” “expect,” “believe,” “anticipate,” “estimate,” “intends,” “goal,” “objective,” “seek,” “attempt,” or variations of these or similar words, identify forward-looking statements.